Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG301 SC in Healthy Subjects and SLE Subjects
NCT06144710Phase 1Completed
- Sponsor
- Shangjian Bio
- Start
- Nov 2023
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing SG301 SC with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events up to 5 months. Started Nov 2023; status: completed.
02
Drugs
SG301
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06144710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144710.